Researchers have engineered a dual-vector adeno-associated virus platform that circumvents the 4.7-kilobase packaging constraint limiting conventional gene therapy. The system enables delivery of full-length proteins like dystrophin and other large therapeutic targets that previously required fragmented approaches with reduced efficacy. This breakthrough addresses a fundamental bottleneck in gene therapy where many disease-relevant proteins exceed single-vector capacity. The dual-vector approach represents a significant advance for treating muscular dystrophies, hemophilia, and other conditions requiring large protein replacement. Previous attempts at split-protein delivery often suffered from poor reassembly efficiency and reduced biological activity. This technology could expand the therapeutic window for AAV-based treatments, particularly for monogenic diseases where full protein function is essential. However, the approach likely increases manufacturing complexity and may face regulatory hurdles requiring dual-vector safety assessment. The system's efficiency in human tissues and long-term stability remain to be demonstrated in clinical trials. If successful, this platform could unlock gene therapy applications for numerous previously untreatable conditions where protein size has been the limiting factor.